Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms

Archive ouverte

Marcault, Clémence | Zhao, Lin-Pierre | Maslah, Nabih | Verger, Emmanuelle | Daltro de Oliveira, Rafael | Soret-Dulphy, Juliette | Cazaux, Marine | Gauthier, Nicolas | Roux, Blandine | Clappier, Emmanuelle | Parquet, Nathalie | Dosquet, Christine | Réa, Delphine | Zini, Jean-Marc | Vainchenker, William | Raffoux, Emmanuel | Giraudier, Stéphane | Kiladjian, Jean-Jacques | Cassinat, Bruno | Benajiba, Lina

Edité par CCSD ; American Society of Hematology -

International audience. Marcault et al report the impact of NFE2 mutations on the prognosis of patients with myeloproliferative neoplasms (MPNs) in a study of over 700 patients for whom sequential next-generation sequencing was available. NFE2 mutations were reported in 9.1% of patients and predicted for increased transformation and decreased survival. Since histone deacetylase (HDAC) inhibitors decrease NFE2 levels, patients with NFE2 mutations may benefit from HDAC inhibitors.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion